Symjepi® (epinephrine) Injection Recall Alert

Date of Notice: March 22, 2022

Brief Description of Recall Alert

Adamis Pharmaceuticals Corporation is voluntarily recalling certain lots of Symjepi® (epinephrine) injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) pre-filled single-dose syringes. The batches are being recalled due to the potential clogging of the needle, preventing the dispensing of epinephrine.

If a person is experiencing an allergic reaction and/or anaphylaxis and is unable to access life-saving epinephrine due to the syringe malfunction, it can lead to life threatening consequences including death.

Affected Products

Drug Name & Strength	NDC	Lot	Expiration Date
Symjepi (epinephrine) Injection, 0.15 mg/0.3 mL	78670-131-02	21101Y	11/30/2022
Symjepi (epinephrine) Injection, 0.3 mg/0.3 mL	78670-130-02	21041W	8/31/2022
		21081W	11/30/2022
		21102W	2/28/2023

Prescriber Information

US WorldMeds is notifying its customers by email, FDA alerts, and direct outreach. Consumers and institutions that have product that are subject to this recall should stop using the product immediately and may either return or discard the recalled lots. Although not confirmed to be related to the recall, there have been two different customer complaints on three syringes, regarding difficulty in dispensing the product, to date. However, neither USWM nor Adamis Pharmaceuticals has received, or is aware of, any adverse events related to this recall.

For questions regarding this recall, use the appropriate Adamis Pharmaceutical Corporation contact information below:

Quality Compliance

- Craig Stenland
  Quality Compliance Partners
  858-361-6456
  craigs@qualpartners.com

Investor Relations

- Robert Uhl
  Managing Director
  ICR Westwicke
  619.228.5886
  robert.uhl@westwicke.com

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Member Information

Members should contact their doctor or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Members with medical-related questions, who wish to report an adverse event or quality issues about the products being recalled, should contact US WorldMeds by phone, (888) 900-8796, or e-mail questions to medinfo@usworldmeds.com Monday-Friday from 8:00 am to 4:00 pm ET.

RxAdvance Response

Members should continue using Symjepi® until a doctor or pharmacist provides replacement drug (if needed) or a different treatment option is given. RxAdvance is in the process of contacting members and prescribers to advise them of this recall.